Currently held
- Agent 20 — SIR Price/Volumelong7 sh @ $227.59 · stop $210.27+$81.27 unrealized
DGX
Quest Diagnostics IncHealth Careinsider_universeLast close $239.28Sep 13, 2026
Day +1.81%
Everything we've seen
- ·Sep 14, 1:35 PMstreamnews
Quest Diagnostics Incorporated (DGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Quest Diagnostics Incorporated (DGX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany ParticipantsSam Samad -...
- ❖Sep 14, 9:11 AMnewsvia finnhub
Quest Diagnostics Incorporated (DGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Quest Diagnostics Incorporated (DGX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany ParticipantsSam Samad -...
- ?Sep 10, 1:45 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is down 2.34% today with no attributable news headline, suggesting the move is driven by broader market or sector flows rather than a specific catalyst. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is a headwind for rate-sensitive sectors broadly — healthcare services/diagnostics like DGX can be indirectly pressured by higher discount rates compressing valuations. However, at 120 minutes remaining, there is meaningful time for continuation but also for mean-reversion. Without a clear catalyst sustaining the selloff and no evidence of a broader sector collapse, the move could easily stall or partially reverse into the close. The absence of headlines cuts both ways — no panic catalyst, but also no fundamental reason to buy the dip aggressively. The 2.34% move is at the lower bound of 'meaningful conviction' territory. Given bounded risk parameters, a slight lean toward continuation is warranted by default, but confidence is low — assigning exactly 0.5 reflecting genuine uncertainty with no strong edge in either direction.
- !Sep 10, 1:45 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
DGX is down 2.34% today with no attributable news headline, suggesting the move is driven by broader market or sector flows rather than a specific catalyst. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is a headwind for rate-sensitive sectors broadly — healthcare services/diagnostics like DGX can be indirectly pressured by higher discount rates compressing valuations. However, at 120 minutes remaining, there is meaningful time for continuation but also for mean-reversion. Without a clear catalyst sustaining the selloff and no evidence of a broader sector collapse, the move could easily stall or partially reverse into the close. The absence of headlines cuts both ways — no panic catalyst, but also no fundamental reason to buy the dip aggressively. The 2.34% move is at the lower bound of 'meaningful conviction' territory. Given bounded risk parameters, a slight lean toward continuation is warranted by default, but confidence is low — assigning exactly 0.5 reflecting genuine uncertainty with no strong edge in either direction.
- ❖Sep 9, 4:01 PMnewsvia finnhub
Apple Health app Users to be Able to Order Labs from Quest Diagnostics
Quest Diagnostics (NYSE: DGX) today announced that Apple Health app users in the United States1 will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. Apple first announced the upcoming update today at its September event.
- ❖Sep 8, 9:21 AMnewsvia finnhub
Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million
J. E. Davis disposed of 8% of his direct equity stake under a pre-planned Rule 10b5-1 trading arrangement, retaining $28.9 million in company stock.
- ❖Sep 8, 8:58 AMnewsvia finnhub
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $245.
- ❖Sep 4, 8:37 PMnewsvia finnhub
Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?
Testing for Alzheimer’s-related brain changes has traditionally depended on procedures that can be expensive, invasive, or difficult to access. Roche Holding AG and Eli Lilly and Company (NYSE:LLY) may now have a simpler way to help physicians evaluate certain patients. The FDA has cleared Elecsys pTau217, which is a blood test that helps identify whether […]
- ❖Sep 4, 10:38 AMnewsvia finnhub
Clinical Laboratory Services Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
The global clinical laboratory services market was valued at USD 274.6 billion in 2025 and is forecast to reach USD 468.2 billion by 2036, rising from USD 298.4 billion in 2026 at a 4.6% CAGR. Growth is driven by chronic diseases, preventive healthcare, molecular diagnostics, genomic testing, precision medicine, laboratory automation, AI-enabled diagnostics, and at-home testing. North America leads, while Asia-Pacific is set for the fastest growth. The report analyzes key segments, regions, oppo
- ❖Sep 4, 1:09 AMnewsvia finnhub
Quest’s Expanded Alzheimer’s and Wellness Testing Push Might Change The Case For Investing In DGX
In recent months, Renalytix PLC, Humanity Health Inc., and Quest Diagnostics have announced new collaborations and product launches, including a nationwide kidneyintelX.dkd testing program, a Humanity Biological Age wellness add-on on questhealth.com, and expanded AD-Detect blood-based Alzheimer’s tests accessible through Quest’s U.S. collection network. Together, these moves highlight Quest’s push to deepen its role in advanced kidney, brain health, and consumer-oriented wellness testing...
- ❖Sep 3, 11:30 AMnewsvia finnhub
Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ?Sep 2, 10:06 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is up 2.18% intraday, a meaningful move suggesting real institutional flow. No news is present, but absence of catalyst is not disqualifying — this is a clean momentum read. The macro context shows 5-year forward inflation expectations (T5YIFR) elevated at 1.7σ above trend, which is a mild headwind for rate-sensitive sectors broadly, but DGX (diagnostics/lab services) is not a primary rate-sensitive name — its business model is more defensive and less directly impacted than financials or REITs. With 340 minutes remaining until the forced close, there is ample time for the move to continue or extend. No reversal signals are indicated, and no fade pattern is described. The setup is ordinary positive momentum with no strong counter-thesis, placing this in the 0.5-0.65 range. The modest inflation premium in rates creates a slight drag on sentiment broadly, preventing a higher conviction score. Overall, lean toward continuation on the basis of momentum and time remaining.
- !Sep 2, 10:06 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
DGX is up 2.18% intraday, a meaningful move suggesting real institutional flow. No news is present, but absence of catalyst is not disqualifying — this is a clean momentum read. The macro context shows 5-year forward inflation expectations (T5YIFR) elevated at 1.7σ above trend, which is a mild headwind for rate-sensitive sectors broadly, but DGX (diagnostics/lab services) is not a primary rate-sensitive name — its business model is more defensive and less directly impacted than financials or REITs. With 340 minutes remaining until the forced close, there is ample time for the move to continue or extend. No reversal signals are indicated, and no fade pattern is described. The setup is ordinary positive momentum with no strong counter-thesis, placing this in the 0.5-0.65 range. The modest inflation premium in rates creates a slight drag on sentiment broadly, preventing a higher conviction score. Overall, lean toward continuation on the basis of momentum and time remaining.
- ❖Aug 31, 4:29 PMnewsvia finnhub
Market Shocks Are Not Where Hims & Hers Health Stock Has Fallen Furthest
Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.
- ❖Aug 24, 3:27 AMnewsvia finnhub
Quest Diagnostics Expands AD‑Detect Portfolio With Two New Blood‑Based Biomarker Tests To Broaden Access For Alzheimer’s Evaluation
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patientsQuest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10%
- ❖Aug 10, 10:44 AMnewsvia finnhub
Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?
LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.
- ❖Aug 10, 9:22 AMnewsvia finnhub
PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down
Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.
- ❖Aug 7, 11:17 AMnewsvia finnhub
PBH Stock Up on Q1 Earnings and Revenue Beat, Fiscal '27 View Raised
Prestige Consumer's Q1 earnings and revenues outpace estimates as acquisitions boost its fiscal 2027 outlook despite margin pressure.
- ❖Aug 7, 11:12 AMnewsvia finnhub
RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y
Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.
- ❖Aug 7, 10:36 AMnewsvia finnhub
Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation
LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.
- ❖Aug 6, 1:42 PMnewsvia finnhub
BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down
BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.
- ❖Aug 6, 11:03 AMnewsvia finnhub
STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading
STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.
- ❖Aug 5, 2:10 PMnewsvia finnhub
Is Quest Diagnostics (DGX) A Bargain Following Raised Guidance And Strong Quarterly Results?
Quest Diagnostics (DGX) has drawn fresh attention after raising its full year 2026 revenue and earnings guidance, alongside reporting second quarter results that showed higher sales and net income versus the prior year. See our latest analysis for Quest Diagnostics. Quest Diagnostics shares have climbed strongly over 2026 so far, with a year to date share price return of 34.48% and a 90 day share price return of 23.58%. That momentum sits alongside a 1 year total shareholder return of 37.26%...
- ❖Aug 5, 2:05 PMnewsvia finnhub
DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.
- ❖Aug 5, 11:47 AMnewsvia finnhub
ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market
ZBH beats second-quarter earnings and revenue estimates, raises its 2026 outlook and gains in pre-market despite pressure on adjusted margins.
- ❖Aug 5, 10:54 AMnewsvia finnhub
CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market
Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.
- ❖Aug 5, 10:20 AMnewsvia finnhub
CVS Health Q2 Earnings and Revenues Top Estimates, Stock Climbs
CVS beats Q2 earnings and revenue estimates as stronger segment performance lifts results and prompts raised 2026 guidance, sending shares higher.
- ❖Aug 5, 10:10 AMnewsvia finnhub
Quest Diagnostics (DGX) Stock May Be 32% Undervalued As Guidance Rises
Quest Diagnostics stock has climbed strongly over the past few years, yet current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach. Quest Diagnostics has returned 83.7% over the past 3 years, which means anyone who held through that period already saw a substantial gain and now needs to judge how much value is left in the current price. Recent strong demand for higher value diagnostic services can support...
- ❖Aug 4, 11:50 AMnewsvia finnhub
IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market
IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.
- ❖Aug 4, 9:33 AMnewsvia finnhub
HSIC Surpasses Q2 Earnings and Revenue Estimates, Stock Climbs
Henry Schein tops Q2 earnings and revenue estimates as internal sales growth accelerates and management raises its 2026 outlook, lifting shares.
- ❖Aug 4, 7:30 AMnewsvia finnhub
Digi Power X to Announce 2026 Q2 Financial Results and Provide Operations Update on August 14th
MIAMI, FL / ACCESS Newswire / August 4, 2026 / Digi Power X Inc. (NASDAQ:DGXX)(Cboe Canada:DGX) (the "Company" or "Digi Power X"), an AI data center infrastructure operator, plans to announce its financial results for the second quarter ended June ...
- ❖Aug 3, 10:37 AMnewsvia finnhub
Quest Diagnostics Raises 2026 Outlook as Testing Demand Accelerates
DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project costs could temper the payoff.
- ❖Aug 3, 8:28 AMnewsvia finnhub
Beat the Market the Zacks Way: Credo, Victoria's Secret, Bank of America in Focus
Credo Technology leads Zacks' latest market-beating highlights as strong stock gains and portfolio performance stand out despite a mixed U.S. economy.
- ▣Aug 2, 8:00 PMjournalrotation
Agent 17 — 52-Week High Momentum closed long 22 @ $231.92 (+$349.80)
52-Week High monthly rebalance. Position dropped from top 20.
- ❖Jul 31, 10:06 AMnewsvia finnhub
Is DGX Stock Worth Buying After Its Strong 2026 Earnings Momentum?
Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.
- ❖Jul 30, 5:38 PMnewsvia finnhub
Is The Sharp Drop In Hims & Hers Health Stock A Reason To Buy?
The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.
- ❖Jul 30, 12:34 PMnewsvia finnhub
Quest Diagnostics Growth Drivers Investors Should Watch Now in 2026
DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.
- ❖Jul 30, 11:29 AMnewsvia finnhub
LH Stock Down Despite Q2 Earnings and Revenue Beat, Margins Rise
Labcorp's Q2 earnings and revenues surpass estimates, margins expand, and its 2026 outlook is raised, but shares fall 6% in pre-market trading.
- ?Jul 30, 9:36 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is down 1.90% today with no clear negative catalyst — the only headline is a neutral/positive clinical study publication, not a market-moving event. The move appears to be flow-driven rather than news-driven. With 369 minutes remaining (over 6 hours, well into the session), there is ample time for continuation or reversal. Macro context shows 5Y inflation expectations 1.5σ below trend, which is mildly supportive of defensive/healthcare names like DGX, creating a small headwind to further downside. However, the magnitude of the move (nearly 2%) suggests real selling conviction, and absent a strong reversal signal or positive catalyst, the path of least resistance slightly favors continuation lower into the close. No reversal pattern is evident from the data provided. The setup is borderline — no strong reason to expect a fade, but macro is mildly unsupportive of further decline. Assigning slight continuation edge given the size of the existing move and absence of a clear bounce catalyst.
- !Jul 30, 9:36 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
DGX is down 1.90% today with no clear negative catalyst — the only headline is a neutral/positive clinical study publication, not a market-moving event. The move appears to be flow-driven rather than news-driven. With 369 minutes remaining (over 6 hours, well into the session), there is ample time for continuation or reversal. Macro context shows 5Y inflation expectations 1.5σ below trend, which is mildly supportive of defensive/healthcare names like DGX, creating a small headwind to further downside. However, the magnitude of the move (nearly 2%) suggests real selling conviction, and absent a strong reversal signal or positive catalyst, the path of least resistance slightly favors continuation lower into the close. No reversal pattern is evident from the data provided. The setup is borderline — no strong reason to expect a fade, but macro is mildly unsupportive of further decline. Assigning slight continuation edge given the size of the existing move and absence of a clear bounce catalyst.
- ❖Jul 30, 7:30 AMnewsvia finnhub
Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
Women who test positive for bacterial vaginosis (BV) were over three times more likely to also test positive for one or more non-viral sexually transmitted infections (STIs) than women who test negative for BV, according to a new Health Trends® study from Quest Diagnostics (NYSE: DGX) and Hologic, Inc.
- ❖Jul 29, 9:01 AMnewsvia finnhub
Boston Scientific Q2 Earnings & Revenues Top Estimates, Stock Climbs
BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.
- ❖Jul 28, 5:48 AMnewsvia finnhub
JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250
JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.
- ❖Jul 27, 4:56 PMnewsvia finnhub
Equinix Stock Has A Message For Management
The company raised its outlook on booming AI demand, but the stock is telling a different story by standing still.
- ❖Jul 26, 10:22 PMnewsvia finnhub
Why Quest Diagnostics Stock Climbed This Past Week
Demand for medical testing services is rising.
- ❖Jul 26, 12:17 AMnewsvia finnhub
Why Quest Diagnostics (DGX) Is Up 8.2% After Raising 2026 Guidance And Boosting Buybacks
Earlier this week, Quest Diagnostics reported second-quarter 2026 results showing sales of US$3,043 million and diluted EPS of US$2.84, and raised its full‑year 2026 revenue guidance to US$11.95–US$12.05 billion and reported EPS to US$9.97–US$10.17. The company also continued its long-running capital return program, repurchasing 522,436 shares for US$100 million in the quarter, which supports earnings per share alongside higher‑value advanced diagnostics and growing test volumes. We’ll now...
- ❖Jul 25, 8:16 PMnewsvia finnhub
Quest Diagnostics (DGX) Stock Gets Fair Value Boost After Q2 Beat And Higher Guidance
Quest Diagnostics is back in focus after analysts lifted Fair Value estimates from US$223.44 to US$239.38, a move that has coincided with price targets shifting into the US$245 to US$265 range for more bullish views and into the low US$230s for more cautious ones. These adjustments reflect how analysts are weighing the Q2 beat, higher full year guidance, and ongoing volume and margin debates when refreshing their models. Read on to see what is driving this evolving narrative and how you can...
- ❖Jul 24, 12:00 PMnewsvia finnhub
Are You Looking for a Top Momentum Pick? Why CSX (CSX) is a Great Choice
Does CSX (CSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- ❖Jul 24, 10:41 AMnewsvia finnhub
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260
Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.
- ❖Jul 24, 10:08 AMnewsvia finnhub
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $225 to $250.
- ❖Jul 24, 9:15 AMnewsvia finnhub
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- ❖Jul 24, 7:08 AMnewsvia finnhub
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $230 to $250.
- ❖Jul 24, 3:33 AMnewsvia finnhub
Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $255
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $236 to $255.
- ❖Jul 24, 1:59 AMnewsvia finnhub
Quest Diagnostics Upgrades EPS Outlook For 2026 After Outperforming Q2 Results
Quest Diagnostics shows Q2 earnings beat, upgraded FY guidance, and continued market momentum. Check out why DGX stock is a buy.
- ❖Jul 23, 8:30 PMnewsvia finnhub
Quest Diagnostics Incorporated Q2 2026 Earnings Call Summary
Moby summary of Quest Diagnostics Incorporated's Q2 2026 earnings call
- ✓Jul 23, 6:03 PMdecisionacted
Agent 20 — SIR Price/Volume — buy
[cluster_break_up] From 2026-07-06 through 2026-07-22, DGX traced a tight consolidation cluster in the $201.77–$210.68 range on persistently subdued volume (ranging from 569K on 2026-07-13 to 1.2M on 2026-07-15), with a trailing 20-day ADV of just 903K — the path sat compressed and range-bound in 2-D PV space. Today's bar (2026-07-23) broke decisively above that cluster: close of $227.59 (+8.46%) on 3.4M shares, a volume z-score of 8.63 — more than eight standard deviations above the recent mean and nearly 3.8× the ADV. In classic SIR cluster_break_up fashion, the dot has migrated sharply up-and-right in a single session, signaling fresh, high-conviction demand absorbing the float that had been quietly distributed in the $201–$210 band over the prior two weeks. Risks: This is a single-bar event — SIR's framework demands multi-session confirmation, and a failure to hold above the $210–$212 breakout shelf in the next 3–5 sessions would re-classify this as an exhaustion/gap-fade rather than a genuine cluster break. Additionally, the macro backdrop (T10Y2Y at 0.36, 1.8σ below trend) signals mild curve flattening pressure that could weigh on risk appetite broadly, and any reversal back into the prior cluster on above-average volume would fully invalidate the bullish read.
- ❖Jul 23, 5:03 PMnewsvia finnhub
Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...
Quest Diagnostics Inc (DGX) reports robust financial performance with a 10% revenue increase, while navigating operational headwinds and strategic investments.
- ❖Jul 23, 3:07 PMnewsvia finnhub
Quest Diagnostics Q2 Earnings Call Highlights
Quest Diagnostics (NYSE:DGX) reported double-digit revenue growth and raised its full-year 2026 outlook after what executives described as strong demand across its physician, hospital and consumer channels, as well as increased volume from major collaborations with Corewell Health and Fresenius Medi
- ❖Jul 23, 3:05 PMnewsvia finnhub
What's going on in today's session: S&P500 movers
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.
- ?Jul 22, 6:04 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[no_pattern] The 20-day PV path for DGX is dominated by a sustained down-and-left drift from the $216 peak on 2026-07-01 through the $201.77 low on 2026-07-15, during which down-day volume was persistently elevated (e.g., 981K on 2026-07-07, 774K on 2026-07-08, 1.2M on 2026-07-15) — a classically distributive signature. Today's bar (2026-07-22, close $209.99, volume 2.9M, z-score +10.04) is a dramatic single-session volume spike, but under SIR methodology one isolated bar — however extreme — cannot confirm a new bullish path; the preceding cluster from 2026-07-09 through 2026-07-21 ($206–$210 range, volumes 569K–992K) has not been decisively broken to the upside with multiple confirming sessions. The spike is more consistent with a climactic event (earnings release or news catalyst) that requires at least one or two follow-through sessions to distinguish genuine accumulation from a one-day exhaustion top within the existing range. Risks: A confirmed follow-through session above $212 on volume ≥ 1.0M in the next 1–3 trading days would upgrade this to a potential cluster_break_up and invalidate the bearish/neutral read. Conversely, any failure to hold the $207–$208 support zone (which acted as the floor from 2026-07-08 through 2026-07-13) on renewed down-day volume expansion would confirm continued distribution and invalidate any bullish interpretation of today's spike.
- ?Jul 7, 11:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is up 2.17% intraday with no attributed headline, suggesting institutional flow or sector rotation into defensives/healthcare. With 285 minutes remaining there is ample time for the move to extend. The macro context shows T10Y2Y at 2.1σ below trend — a flatter/slightly inverted curve environment — which historically favors defensive sectors like healthcare/diagnostics over cyclicals, providing mild tailwind for DGX. No reversal pattern is evident from available data, and absence of news does not negate the momentum signal. However, the move is at the lower bound of the 2-5% meaningful-flow range (~2.2%), limiting conviction. No volume data is available to confirm institutional commitment, which prevents a higher probability rating. Overall, the defensive sector macro tailwind combined with a real but moderate intraday move and ample time remaining supports a lean toward continuation, but without volume confirmation or a catalyst this is a borderline read.
- !Jul 7, 11:01 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
DGX is up 2.17% intraday with no attributed headline, suggesting institutional flow or sector rotation into defensives/healthcare. With 285 minutes remaining there is ample time for the move to extend. The macro context shows T10Y2Y at 2.1σ below trend — a flatter/slightly inverted curve environment — which historically favors defensive sectors like healthcare/diagnostics over cyclicals, providing mild tailwind for DGX. No reversal pattern is evident from available data, and absence of news does not negate the momentum signal. However, the move is at the lower bound of the 2-5% meaningful-flow range (~2.2%), limiting conviction. No volume data is available to confirm institutional commitment, which prevents a higher probability rating. Overall, the defensive sector macro tailwind combined with a real but moderate intraday move and ample time remaining supports a lean toward continuation, but without volume confirmation or a catalyst this is a borderline read.
- !Jul 2, 9:47 AMsignal
options_momentum — insufficient_capital
- !Jul 2, 9:35 AMsignal
options_momentum — insufficient_capital
- !Jul 2, 9:17 AMsignal
options_momentum — insufficient_capital
- !Jul 2, 9:05 AMsignal
options_momentum — insufficient_capital
- !Jul 2, 7:04 AMsignal
options_momentum — insufficient_capital
- ▣Jul 1, 8:00 PMjournalmanual
Agent 5 — Dip Buyer (Evolving) closed long 1 @ $213.67 (+$19.47)
Target hit (partial-rounded-to-full): close $216.02 ≥ target $209.79
- ▢Jul 1, 8:00 PMjournal
Agent 17 — 52-Week High Momentum opened long 22 @ $216.02
- !Jul 1, 5:46 PMsignal
options_momentum — insufficient_capital
- !Jul 1, 5:32 PMsignal
options_momentum — insufficient_capital
- !Jul 1, 5:17 PMsignal
options_momentum — insufficient_capital
- !Jul 1, 5:03 PMsignal
options_momentum — insufficient_capital
- !Jul 1, 4:47 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 5:46 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 5:31 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 5:16 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 5:04 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 4:46 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 4:33 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 2:49 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 2:36 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 2:19 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 1:48 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 1:35 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 12:49 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 12:35 PMsignal
options_momentum — insufficient_capital
- !Jun 30, 11:49 AMsignal
options_momentum — insufficient_capital
- !Jun 30, 10:51 AMsignal
options_momentum — insufficient_capital
- !Jun 30, 9:49 AMsignal
options_momentum — insufficient_capital
- ▣Jun 29, 8:00 PMjournaltarget
Agent 5 — Dip Buyer (Evolving) closed long 1 @ $211.80 (+$17.60)
Staged exit (1/2.0): close $211.80 ≥ target $209.79. Selling 1/2 sh, trailing remainder.
- ▣Jun 29, 8:00 PMjournalmanual
Agent 5 — Dip Buyer (Evolving) closed long 1 @ $207.97 (+$13.77)
Staged exit (1/2.0): close $212.64 ≥ target $209.79. Selling 1/3 sh, trailing remainder.
- ▣Jun 28, 8:00 PMjournaltarget
Agent 5 — Dip Buyer (Evolving) closed long 2 @ $212.71 (+$37.01)
Staged exit (1/2.0): close $212.71 ≥ target $209.79. Selling 2/5 sh, trailing remainder.
- ▣Jun 28, 8:00 PMjournalmanual
Agent 5 — Dip Buyer (Evolving) closed long 4 @ $207.97 (+$55.06)
Staged exit (1/2.0): close $209.88 ≥ target $209.79. Selling 4/9 sh, trailing remainder.
- ✓Jun 25, 9:56 AMdecisionacted
Agent 5 — Dip Buyer (Evolving) — pyramid
Pyramid add-on fired at +10.00% unrealized. Added 3 sh @ $206.74 ($620.21). Position now 9 sh @ weighted avg $194.20.
- ?Jun 25, 9:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is up 1.53% intraday, a moderate but not outsized move. There are no catalysts or headlines to explain the move, suggesting it may be flow-driven rather than news-driven. The macro context shows T10YIE significantly below trend (2.4σ), indicating compressed inflation expectations, which is broadly neutral-to-supportive for healthcare/diagnostics names like DGX that are not heavily rate-sensitive. With 360 minutes remaining (essentially a full session still ahead), there is ample time for continuation, but also ample time for a fade. The move is below the 2% threshold that would signal strong conviction. No reversal signals are evident from the data provided. Overall, a mild lean toward continuation given time remaining and supportive macro backdrop, but conviction is low — probability sits just above the neutral threshold.
- ?Jun 23, 11:26 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is up 1.89% with 260 minutes (over 4 hours) remaining, providing ample time for continuation. The move is meaningful but sits below the 2-5% high-conviction threshold, so momentum evidence is moderate. No news headlines are present, which is neutral per guidance. The macro context shows T10YIE at 1.7σ below trend, indicating compressed inflation expectations — this is mildly supportive for healthcare/diagnostics names like DGX, which are not long-duration sensitive and thus not adversely affected by low real rates. There is no reversal signal or fade pattern described. With no countervailing catalyst, the default lean is mild continuation. Probability set at 0.54: modest upward bias given the existing move, time available, and neutral-to-supportive macro, but held below 0.6 due to the sub-2% move magnitude and absence of any identifiable catalyst confirming sustained institutional buying.
- ?Jun 23, 10:15 AMdecisionconsidered
Agent 7 — Day Trader — analyze: fail
Claude analysis failed: Anthropic 500: {"type":"error","error":{"type":"api_error","message":"Internal server error"},"request_id":"req_011CcLLDzNQe4GyL3Kp2GrTo"}
- ?Jun 17, 10:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
- ?Jun 9, 10:42 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is up 1.80% today with no attributable headline, suggesting this is flow-driven rather than news-driven. At ~1.80% the move is meaningful but not yet at a magnitude that typically signals exhaustion. With 304 minutes remaining (essentially a full afternoon session), there is ample time for continuation. The macro context shows a compressed yield curve (T10Y2Y at 2.0σ below 24-month trend), which tends to benefit defensives like healthcare/lab diagnostics — DGX fits this profile as a defensive, non-cyclical name. This is modestly supportive of the upward move. No reversal signals are evident from the data provided. The absence of news is not disqualifying per framework guidance. Overall this is an ordinary momentum setup with mild macro tailwind, warranting a modest continuation probability above 0.5 but not a high-conviction call.
- ?Jun 5, 9:35 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is up 1.67% today, a moderate but not exceptional intraday move. With 370 minutes remaining (well over 6 hours), there is ample time for the move to continue or extend into the close, which is a mild positive. The macro context shows T10Y2Y at 1.9σ below trend, which is modestly flattening/bear-flattening — this tends to favor defensives like healthcare/lab services names such as DGX, providing a slight tailwind. The only headline is a generic pre-market mover recap with no DGX-specific negative catalyst identified. Absence of a clear reversal catalyst, combined with the defensive sector tilt being supportive in the current macro environment, keeps momentum leaning positive. However, the move is not large enough to signal strong institutional conviction, and the macro read is indirect. No reversal pattern is evident. Overall, a modest continuation probability above the 0.5 threshold is warranted.
- ?May 19, 9:05 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is up 1.73% intraday, a modest but real move reflecting genuine buying flow. No news catalyst is present, which is common and not disqualifying. With 400 minutes remaining (well over a full session), there is ample time for continuation. However, the macro context is modestly cautionary: T10YIE is running 2.4σ above trend, suggesting elevated inflation expectations which can pressure defensive/dividend-sensitive healthcare names like DGX at the margin. The move itself is below the 2% threshold that would signal strong conviction, so this is an ordinary momentum read rather than a high-conviction setup. No reversal signals are evident from the data provided. Net assessment: slight edge to continuation given time remaining and the positive flow signal, but macro headwinds cap confidence. Probability sits just above the 0.5 threshold.
- ?May 18, 9:25 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
Quest Diagnostics is a fundamentally solid business — a recent article highlights strong profitability and financial health, and it carries a reliable dividend. The 11% drop appears to be largely sector-driven, as Health Care (XLV) is ranked 10 of 11 in 30-day relative strength with a -13.87pt sector underperformance vs SPY, suggesting DGX is caught in a broad sector selloff rather than experiencing company-specific deterioration. However, confirmation signals are absent: no insider buying, no unusual call flow (put/call ratio of 8.88 is extremely elevated, indicating heavy put activity), and no SEC filings clarifying the move.
- ?May 18, 8:54 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
DGX (Quest Diagnostics) is a large-cap, defensive healthcare services company with stable recurring revenue from laboratory testing — no recent SEC filings or news headlines suggest fundamental deterioration, so the 11% pullback from the 30-day high appears to reflect broad macro pressure rather than company-specific issues. The elevated 5-year breakeven inflation rate (2.7%, 2.5σ above trend) signals a risk-off rotation into inflation-hedged assets and away from stable-growth defensives, which could explain near-term multiple compression. However, with no confirming catalyst for the drop and DGX's historically resilient earnings profile, a partial mean-reversion toward the prior high over 90 days is plausible but not highly probable given the macro headwind.
- ?May 16, 6:35 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $6.08 cash available; close=$186.61.
- ?May 16, 10:05 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX is down 11% from its 30-day high at $186.61, but the evidence base is almost entirely empty: no recent news headlines, no SEC filings, no insider activity, no options flow, and no upcoming earnings catalyst to anchor a rebound thesis. The macro backdrop is mixed-to-negative for a swing entry: broad market is broadly selling off today (SPY -1.20%, IWM -2.41%), VIX is at the 50th percentile (not extreme fear, so no contrarian capitulation signal), the 10Y yield at 4.47% is near the structural headwind threshold, and 5-year inflation breakevens printing 2.7 (2.5σ above trend) suggest a rates/inflation repricing that could pressure valuation multiples on defensive healthcare names. Without a confirmed sector-wide selloff as the culprit (no sector flow data), the idiosyncratic nature of the drop is unexplained, which increases uncertainty rather than providing a clear dip-buying rationale. The absence of any cluster insider buying removes what would otherwise be the most reliable positive signal for a fundamentals-oriented value trade. Healthcare/diagnostics is a relatively defensive sector, and DGX has reasonable fundamental characteristics generally, but with no confirmatory evidence and a deteriorating near-term macro tone, the risk/reward for a 90-day swing trade is not sufficiently favorable.
- ?May 16, 9:00 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
DGX (Quest Diagnostics) is a large-cap, defensive healthcare services company with stable recurring revenue from laboratory testing — no recent SEC filings or news headlines suggest fundamental deterioration, so the 11% pullback from the 30-day high appears to reflect broad macro pressure rather than company-specific issues. The elevated 5-year breakeven inflation rate (2.7%, 2.5σ above trend) signals a risk-off rotation into inflation-hedged assets and away from stable-growth defensives, which could explain near-term multiple compression. However, with no confirming catalyst for the drop and DGX's historically resilient earnings profile, a partial mean-reversion toward the prior high over 90 days is plausible but not highly probable given the macro headwind.
- ?May 16, 8:58 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
- ?May 15, 6:37 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
- ?May 15, 6:33 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
- ?May 15, 6:24 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
- ?May 15, 6:15 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
- ?May 15, 3:38 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
- ?May 15, 9:18 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is down 1.52% with 387 minutes remaining — a modest but real move with ample time left in the session. The move is below the 2-5% threshold that would signal high conviction institutional flow, so it reads more as routine selling pressure than a decisive directional break. No news catalysts are present to explain or amplify the move, which is neutral rather than disqualifying. The macro context (5Y inflation expectations 2.5σ above trend) is modestly negative for rate-sensitive healthcare names like DGX insofar as elevated inflation expectations can pressure multiple expansion, but DGX is not a primary reactor to TIPS/gold/energy dynamics — so macro provides only weak incremental support for continuation. With no reversal signals evident and time still ample, there is no strong reason to fade the current direction. Assigning the floor continuation probability of 0.5 — momentum is present but not compelling enough to rate higher without volume confirmation or a cleaner macro/news catalyst.
- ?May 15, 9:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is down 1.52% with no attributable news catalyst, placing this in the ordinary momentum category. The move is meaningful but below the 2-5% threshold that would signal strong conviction flow. With 404 minutes remaining (essentially a full trading day still ahead from mid-morning), there is ample time for continuation, but also ample time for mean reversion. The macro context (elevated 5Y breakeven inflation at 2.5σ above trend) is not directly relevant to DGX, a healthcare/diagnostics name — DGX is not in Gold, Energy, or TIPS sectors, so macro context neither supports nor undermines the move. No headlines to explain the selloff, which is common and not disqualifying. With no reversal signals noted, no thin volume warning, and time remaining supportive of continuation, the base case is weak continuation momentum. Assigning 0.50 — the minimum threshold — reflecting the absence of both a strong continuation signal and a strong reversal signal. The bounded risk profile (1.5% stop, 3% target) justifies taking this borderline read at exactly the cutoff.
- ✓May 14, 9:36 PMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
DGX (Quest Diagnostics) is a defensively positioned, cash-generative healthcare services company with a durable business model built on recurring lab testing demand. The 10.4% pullback from its 30-day high occurs against a broadly constructive market backdrop today (SPY +0.79%, VXX -2.54%), suggesting the decline is likely idiosyncratic rather than macro-driven, though the absence of recent news or filings makes it difficult to pinpoint a catalyst. The elevated 5-year inflation expectations (T5YIE at 2.5σ above trend) could weigh on multiple expansion for defensive healthcare names, but DGX's pricing power and contract structures partially insulate it.
- ✓May 14, 9:35 PMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
DGX (Quest Diagnostics) is a well-established, defensive healthcare services company with stable cash flows and no recent negative filings or headlines to explain the 10.4% drop from its 30-day high, suggesting the move may be technically driven or linked to broader sector rotation rather than fundamental deterioration. The broad market tone today is constructively positive (SPY +0.79%, VXX -2.54%), which means the idiosyncratic weakness in DGX is notable but not panic-driven, and the lack of confirming negative news raises the probability of mean reversion. The elevated 5-year inflation expectations (T5YIE at 2.5σ above trend) are a mild headwind for valuation multiples but do not directly impair a diagnostics business model.
- ?May 14, 9:34 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
DGX (Quest Diagnostics) is a defensively positioned healthcare services company with stable recurring revenue from diagnostic testing, manageable debt, and consistent free cash flow generation — no recent filings or headlines indicate fundamental deterioration. The 10.4% drawdown from the 30-day high appears attributable to macro rotation rather than company-specific issues, potentially driven by rising inflation expectations (T5YIE at 2.7, 2.5σ above trend) pressuring rate-sensitive, lower-growth defensive equities and prompting rotation into inflation-benefiting sectors. However, the absence of any recent news or filings creates meaningful informational uncertainty about whether a catalyst for recovery exists within the 90-day window.
- ?May 14, 9:34 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
- ?May 14, 9:33 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
DGX (Quest Diagnostics) is a defensively positioned healthcare services company with stable recurring revenue from diagnostic testing, manageable debt, and consistent free cash flow generation — no recent filings or headlines indicate fundamental deterioration. The 10.4% drawdown from the 30-day high appears attributable to macro rotation rather than company-specific issues, potentially driven by rising inflation expectations (T5YIE at 2.7, 2.5σ above trend) pressuring rate-sensitive, lower-growth defensive equities and prompting rotation into inflation-benefiting sectors. However, the absence of any recent news or filings creates meaningful informational uncertainty about whether a catalyst for recovery exists within the 90-day window.
- ?May 14, 9:33 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
- ?May 14, 9:26 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
DGX (Quest Diagnostics) is a defensively positioned healthcare services company with stable recurring revenue from diagnostic testing, manageable debt, and consistent free cash flow generation — no recent filings or headlines indicate fundamental deterioration. The 10.4% drawdown from the 30-day high appears attributable to macro rotation rather than company-specific issues, potentially driven by rising inflation expectations (T5YIE at 2.7, 2.5σ above trend) pressuring rate-sensitive, lower-growth defensive equities and prompting rotation into inflation-benefiting sectors. However, the absence of any recent news or filings creates meaningful informational uncertainty about whether a catalyst for recovery exists within the 90-day window.
- ?May 14, 9:24 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
- ▢May 14, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 2 @ $194.20
- ▢May 14, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 4 @ $194.20
- ▢May 14, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 1 @ $194.20
- ▢May 14, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 1 @ $194.20
- ▢May 14, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 1 @ $194.20
- ?May 14, 2:03 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is down 1.36% today, which is a moderate but not dramatic move. The absence of any news catalyst makes it harder to assess whether real conviction is behind this sell-off or whether it's noise/light selling pressure. The macro context (elevated 5Y inflation breakevens at 2.5σ above trend) is most relevant to Gold, Energy, and TIPS sectors — not directly to DGX (Quest Diagnostics, a healthcare/diagnostics company), so macro provides no meaningful tailwind or headwind for continuation. With 102 minutes remaining, there is ample time for a move in either direction, but the lack of a clear catalyst and the modest magnitude (-1.36%, well below the 2-5% threshold that signals strong conviction flow) suggests this could easily fade or reverse into the close as intraday sellers cover. No reversal pattern is confirmed yet, but the setup does not present strong continuation pressure. Marginally below the 0.5 threshold — not taking the trade.